Podrobno

Dopolnilno in dodatna zdravstvena zavarovanja : diplomsko delo visokošolskega programa
ID Nusdorfer, Barbara (Avtor), ID Pevcin, Primož (Mentor) Več o mentorju... Povezava se odpre v novem oknu

.pdfPDF - Predstavitvena datoteka, prenos (1,76 MB)
MD5: E280D7D13288943AF44DBA47EFC99F65
PID: 20.500.12556/rul/3b32b2a4-dde0-4fdc-84aa-42901e6caaca

Jezik:Slovenski jezik
Ključne besede:zdravstveno zavarovanje, zavarovalnice, zdravstvo, diplomska naloge
Vrsta gradiva:Diplomsko delo/naloga
Tipologija:2.11 - Diplomsko delo
Organizacija:FU - Fakulteta za upravo
Kraj izida:Ljubljana
Založnik:[B. Nusdorfer]
Leto izida:2009
Št. strani:V, 65 str.
PID:20.500.12556/RUL-20911 Povezava se odpre v novem oknu
UDK:368.942(043.2)
COBISS.SI-ID:3302062 Povezava se odpre v novem oknu
Datum objave v RUL:11.07.2014
Število ogledov:2761
Število prenosov:384
Metapodatki:XML DC-XML DC-RDF
:
NUSDORFER, Barbara, 2009, Dopolnilno in dodatna zdravstvena zavarovanja : diplomsko delo visokošolskega programa [na spletu]. Diplomsko delo. Ljubljana : B. Nusdorfer. [Dostopano 29 marec 2025]. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=20911
Kopiraj citat
Objavi na:Bookmark and Share

Podobna dela

Podobna dela v RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Podobna dela v drugih slovenskih zbirkah:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Nazaj